BioTuesdays

Category - Markets

Fennec Pharmaceuticals Logo
Markets

Maxim ups Fennec PT to $15 on PEDMARK approval

Maxim Group raised its price target for Fennec Pharmaceuticals (NASDAQ:FENC) to $15 from $10, and maintained its “buy” rating, after FDA approval of PEDMARK, its formulation of sodium thiosulfate for the prevention of...

September 29, 2022
Cognition Logo
Markets

Cantor starts Cognition at OW; PT $12

Cantor Fitzgerald launched coverage of Cognition Therapeutics (NASDAQ:CGTX) with an “overweight” rating and 12-month price target of $12. The stock closed at $1.74 on Sept. 28. Cognition is a neuro-innovator leveraging...

September 29, 2022
Akouos
Markets

WB starts Akouos at OP; fair value estimate $12

William Blair launched coverage of Akouos (NASDAQ:AKUS) with an “outperform” rating and fair value estimate of $12. The stock closed at $5.10 on Sept. 28. Akouos is developing a pipeline of gene therapies delivered...

September 29, 2022
BioRestorative Therapies Logo
Markets

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...

September 28, 2022
Everest Medicines Logo
Markets

HCW starts Everest Medicines at buy; PT $30 HK

H.C. Wainwright launched coverage of Everest Medicines (HKSE:1952.HK) with a “buy” rating and price target of $30 HK. The stock closed at $10.38 HK on Sept. 8. Everest Medicines is an integrated biopharmaceutical...

September 9, 2022
Annexon Logo
Markets

BTIG starts Annexon at buy; PT $15

BTIG initiated coverage of Annexon (NASDAQ:ANNX) with a “buy” rating and $15 price target. The stock closed at $6.02 on Sept. 8. Annexon, Inc. is a development-stage biotech company focused on mediating the role of...

September 9, 2022
Asensus Surgical Logo
Markets

Cantor starts Asensus Surgical at OW; PT $1.50

Cantor Fitzgerald initiated coverage of Asensus Surgical (NYSE American:ASXC) with an “overweight” rating and price target of $1.50. The stock closed at 53 cents on Sept. 7. Asensus is a robotic-assisted surgery company...

September 8, 2022